Rapid decline in insulin antibodies and glutamic acid decarboxylase autoantibodies with ibrutinib therapy of chronic lymphocytic leukaemia

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2710|43|1|145-149

ISSN： 0269-4727

Source： JOURNAL OF CLINICAL PHARMACY & THERAPEUTICS, Vol.43, Iss.1, 2018-02, pp. : 145-149

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 180, Iss. 5, 2018-03 ,pp. : 666-679

John Wiley & Sons Inc

Access to resources Recommend Favorite

Ibrutinib is an effective treatment of autoimmune haemolytic anaemia in chronic lymphocytic leukaemia

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 170, Iss. 5, 2015-09 ,pp. : 734-736

John Wiley & Sons Inc

Access to resources Recommend Favorite

Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non‐Hodgkin lymphoma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 170, Iss. 4, 2015-08 ,pp. : 445-456

John Wiley & Sons Inc

Access to resources Recommend Favorite

(Pseudo)hemidystonia associated with anti‐glutamic acid decarboxylase antibodies – a case report

By  

EUROPEAN JOURNAL OF NEUROLOGY, Vol. 22, Iss. 12, 2015-12 ,pp. : 1573-1574

John Wiley & Sons Inc

Access to resources Recommend Favorite

Rituximab Therapy in Cutaneous Infiltration of Chronic Lymphocytic Leukaemia

By  

Acta Haematologica, Vol. 130, Iss. 1, 2013-02 ,pp. : 47-51

Karger

Access to resources Recommend Favorite